



E-learning Module 3 - Antiretroviral therapy

Tutorial B - ART and patient wellbeing

References

1. Bangsberg DR. A paradigm shift to prevent HIV drug resistance. *PLoS Med* 2008; 5: e111.
2. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. *AIDS* 2009; 23: 1035–1046.
3. Cambiano V, Lampe FC, Rodger AJ *et al.* Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression. *HIV Med* 2010; 11: 216–224.
4. Ingersoll KS, Farrell-Carnahan L, Cohen-Filipic J *et al.* A pilot randomized clinical trial of two medication adherence and drug use interventions for HIV+ crack cocaine users. *Drug Alcohol Depend* 2011; 116: 177–187.
5. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. *J Acquir Immune Defic Syndr* 2011; 58: 181–187.
6. Horne R, Weinman J, Barber N *et al.* Concordance, adherence and compliance in medicine taking: a conceptual map and research priorities. London: National Institute for Health Research (NIHR) Service Delivery and Organisation (SDO) Programme; 2006. Available at: <https://njl-admin-test.nihr.ac.uk/document/download/2107261> (accessed November 2016).
7. National Collaborating Centre for Primary Care. Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence. NICE clinical guideline 76 (CG76). 2009. Available at: <http://guidance.nice.org.uk/CG76> (accessed November 2016).
8. British Psychological Society, British HIV Association, Medical Foundation for AIDS and Sexual Health. Standards for psychological support for adults living with HIV. 2011. Available at: www.bhiva.org/StandardsForPsychologicalSupport.aspx (accessed November 2016).
9. Langebeek N, Gisolf EH, Reiss P *et al.* Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. *BMC Med* 2014; 12: 142.
10. Bartlett JA. Addressing the challenges of adherence. *J Acquir Immune Defic Syndr* 2002; 29(Suppl 1): S2–10.
11. Stevenson J, Browne D, Otoro I, Duffy A. The impact of faith-based 'healing' and 'cure' claims on Africans living with HIV in the UK. Poster 13 (P13) available at <https://www.bhiva.org/file/OXPvRwMZeunYg/P13.pdf> (accessed June 2017).

12. Katz IT, Ryu AE, Onuegbu AG *et al.* Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. *J Int AIDS Soc* 2013; 16(3 Suppl 2): 18640.
13. Stutterheim SE, Bos AE, Shiripinda I *et al.* HIV-related stigma in African and Afro-Caribbean communities in the Netherlands: manifestations, consequences and coping. *Psychol Health* 2012; 27: 395–411.
14. British HIV Association. Standards of Care for People Living with HIV 2013. Available at: <https://www.bhiva.org/file/WSheCFExXGBRK/BHIVASStandardsA4.pdf> (accessed May 2016).
15. Brough, G. Peer support in HIV care. *HIV Nursing* 2016; 16: 26–28
16. Heath KV, Singer J, O'Shaughnessy MV, Montaner JS, Hogg RS. Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. *J Acquir Immune Defic Syndr* 2002; 31: 211–217.
17. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. *Am J Psychiatry* 2001; 158: 725–730.
18. Churchill D, Waters L, Ahmed N *et al.* BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. Available at: <https://www.bhiva.org/file/jvPQXcViUbtgr/2015-treatment-guidelines.pdf> (accessed May 2017).
19. Mollan KR, Smurzynski M, Eron JJ *et al.* Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. *Ann Intern Med* 2014; 161: 1–10.
20. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients. *Am J Kidney Dis* 2011; 57: 773–780.
21. British Heart Foundation Cardiovascular Disease in the UK. Available at: <https://www.bhf.org.uk/what-we-do/our-research/heart-statistics> (accessed Nov 2016).
22. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. *HIV Med* 2012; 13: 453–468.
23. Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. *Eur Heart J* 2014; 35: 1373–1381.
24. Feeney, GR, Mallon PW. HIV and HAART-associated dyslipidemia. *Open Cardiovasc Med J* 2011; 5: 49–63.
25. Friis-Moller N, Weber R, Reiss P *et al.* Cardiovascular disease risk factors in HIV patients –association with antiretroviral therapy. Results from the DAD study. *AIDS* 2003; 17: 1179–1193.
26. El-Sadr WM, Lundgren J, Neaton JD *et al.* CD4+ count-guided interruption of antiretroviral treatment. *N Engl J Med* 2006; 355: 2283–2296.
27. The Insight START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. *New Eng J Med* 2015; 373: 795–807.
28. Lundgren JD, Battegay M, Behrens G *et al.* European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. *HIV Medicine* 2008; 9: 72–81 DOI: 10.1111/ j.1468-1293.2007.00534.x (accessed May 2017).
29. Shindel AW, Horberg MA, Smith JF, Brevier BN. Sexual dysfunction, HIV, and AIDS in men who have sex with men. *AIDS Patient Care STDS* 2011; 25: 341–349.

30. Walker Harris V, Brown TT. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. *J Infect Dis* 2012; 205 (Suppl 3): S391–398.
31. Cotter AG, Sabin CA, Simelane S *et al.* Relative contribution of HIV infection, demographics and body mass index to bone mineral density. *AIDS* 2014; 28: 2051–2060.
32. McComsey GA, Tebas P, Shane E *et al.* Bone disease in HIV infection: a practical review and recommendations for HIV care providers. *Clin Infect Dis* 2010; 51: 937–946.
33. Childs K, Welz T, Samarawickrama A, Post FA. Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients. *AIDS* 2012; 26: 253–262.
34. Sherr L, Lampe F, Norwood S *et al.* Successive switching of antiretroviral therapy is associated with high psychological and physical burden. *Int J STD AIDS* 2007; 18: 700–704.